Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of goal-directed fluid therapy based on plasma colloid osmotic pressure on the postoperative pulmonary complications of elderly patients undergoing major abdominal surgery

ABSTRACT: Interventions: Group 1:Total fluid input = physiological requirement + preoperative cumulative loss + continuing loss + third space loss + compensatory volume expansion;Group 2:Goal-directed fluid therapy based on stroke volume variation;Group 3:Goal-directed fluid therapy based on stroke volume variation and plasma colloid osmotic pressure Primary outcome(s): Indicators of changes in lung function;Postoperative pulmonary complications occurring within 7 days after surgery;Lung injury score Study Design: Parallel

DISEASE(S): Gastric And Colorectal Cancer

PROVIDER: 2705802 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Application of GDFT combined with low dose metaraminol in elderly patients undergoing laparoscopic radical resection of colorectal cancer

Project description:Interventions: Group C:Routine infusion ; Group G:Goal-directed fluid therapy;Group GM:goal-directed fluid therapy combined with low-dose metaraminol Primary outcome(s): Mean arterial pressure;Cardiac output;Heart index;Stroke volume Study Design: Randomized parallel controlled trial

| 2680686 | ecrin-mdr-crc

Effects of Goal-directed Fluid Therapy guided by SVV on intestinal barrier function in patients undergoing colon cancer surgery

Project description:Interventions: Group GDFT:Goal-directed fluid therapy;Group control:Traditional fluid therapy Primary outcome(s): IFABP;D-lactic acid;SVV;CI;Q-40 score Study Design: Parallel

| 2700173 | ecrin-mdr-crc

Effect of goal-directed fluid therapy on glycocalyx in elderly patients with colorectal cancer and its mechanism

Project description:Interventions: control group:nothing;treatment group:goal-directed fluid therapy Primary outcome(s): TNF-a;heparan sulfate;syndecan-1 Study Design: Parallel

| 2741182 | ecrin-mdr-crc

Comparison of Three Different Liquid Therapy in Colorectal Surgery

Project description:Interventions: R group (restricted fluid treatment group):Rrestricted fluid ;W group (Wash-out liquid treatment group):Open fluid input and furosemide are given ;Group G (Goal-directed fluid therapy group):Goal-directed fluid therapy Primary outcome(s): blood pressure;Heart Rate;IL-6;CRP;TNF-a Study Design: Randomized parallel controlled trial

| 2676166 | ecrin-mdr-crc

The effect of usual versus limited fluid therapy in children undergoing abdominal, chest and genitourinary surgery.

Project description:Intervention1: Restricted fluid therapy: During intra-operative period, restricted fluid therapy group will receive maintenance and deficit correction as per Holliday-Segar formula and blood loss replacement (3:1 with Ringers lactate and 1:1 with blood according to anaesthesiologists decision). Fluid bolus will be given at 5ml/kg if stroke volume variation (SVV) in electrical cardiometry is more than 15% persistently for more than 5 min. At the end of surgery number of fluid boluses, serum lactate, sodium, potassium, calcium, blood urea and creatinine will be measured. Chest x ray will be taken in immediate post-operative period to look for signs of fluid overload. Assessment for nausea and vomiting will be done, weight will be checked if posssible. On post-operative day 2, blood urea and serum creatinine will be checked. Duration of hospital stay will be noted. Control Intervention1: Standard fluid therapy: During intra-operative period, standard fluid therapy group will receive maintenance and deficit fluid correction as per Holliday-Segar formula, blood loss replacement and 3rd space loss replacement(4-7ml/kg for thoracotomy, 5-10ml/kg for abdominal surgery). Electrical cardiometry will be monitored in this group also. At the end of surgery number of fluid boluses, serum lactate, sodium, potassium, calcium, blood urea and creatinine will be measured. Chest x ray will be taken in immediate post-operative period to look for signs of fluid overload. Assessment for nausea and vomiting will be done, weight will be checked if posssible. On post-operative day 2, blood urea and serum creatinine will be checked. Duration of hospital stay will be noted. Primary outcome(s): 1.Postoperative hypernatremia 2.Rise in serum lactate 3.Rise in blood urea 4.Rise in serum creatinine Timepoint: At the end of surgery

| 28494 | ecrin-mdr-crc

A clinical study to see the effects of two different methods of fluid administration (Fluid volumeestimated by anaesthetist compared with volume estimated by a machine) during Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Project description:Intervention1: Stroke volume variation (SVV) (using Flotrac) guided fluid therapy: The CI will be maintained at values greater than or equal to 2.5 l/min/m2 , stroke volume variation 12%, Stroke Volume Index (SVI) 35ml/m2/ beat, Systemic Vascular Resistance Index (SVRI) more than equal to 1900 dynes-sec/cm-5/m2 . Basal infusion of crystalloids will be at 4 ml/kg/h. If CI 2.5 l/min/m2, SVI 35 ml/m2 and SVV 12% crystalloid challenge and colloid bolus will be given. In the case of CI 2.5 l/min/m2 and SVI 35 ml/m2 with SVV 12% an infusion with dobutamine will be initiated alongwith colloid bolus. Control Intervention1: Fluid therapy guided by clinical parameters like mean arterial pressure (MAP), central venous pressure (CVP) and urine output: to maintain end organ perfusion, general fluid management with IV infusion of crystalloid (lactate free) will be done aiming at a Mean arterial pressure (MAP) of 65 mm Hg, urinary output of at least 0.5 (CRS phase), 2 (HIPEC phase), and 1 (post HIPEC phase) ml/ kg/ hr, respectively and CVP of 8-12 mm hg. Basal infusion of crystalloid will be at 4 ml/kg/hour, with bolus of crystalloid, colloid and use of noradrenaline depending on MAP, Urine output and CVP. Primary outcome(s): Serum Lactate levelsTimepoint: At baseline, then at one hour interval during Cytoreductive phase, half hourly interval during HIPEC phase and every 6 hourly interval post operatively for 24 hours. Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant Blinded

| 2597788 | ecrin-mdr-crc

The Application of Pleth Variability Index in Continuous Monitoring the Volume Status of Intraoperative Patients

Project description:To assess the value of using pleth variability index(PVI) to monitor the patient’s intra-operative volume status continuously by observing the application of stroke volume variation(SVV) and PVI and their correlation in patients undergoing intestinal tumor surgeries.

| 2233359 | ecrin-mdr-crc

Expression data from rat (Sprague Dawley) brain subjected to MCAo.

Project description:Middle cerebral artery occlusion (MCAo) in rat represent the ischemic stroke in human. Rodents subjected to MCAo and treated with venom phospholipase A2 showed reduction in infarct volume after 24hours of stroke. We studied the global gene expression of the reduction in infarct volume using Affymetrix Gene Chips. We analysed all the genes that were up or down regulated in the study. Total RNA isolated from sham, MCAo and MCAo+nPLA rat brains, was pooled to minimize inter-individual variation and hybridized to each array of the RAE-230A or U34A GeneChipTM according to protocols described in the GeneChipTM expression analysis package (Affymetrix, CA).

2009-09-04 | E-GEOD-17929 | biostudies-arrayexpress

Astrocyte-derived thrombospondins 1 and 2 are required for cortical synapse development controlling goal-directed action performance.

Project description:Astrocyte-derived thrombospondins 1 and 2 are required for cortical synapse development controlling goal-directed action performance.

| PRJNA1080221 | ENA

Clinical significance and analysis of related risk factors of hyperamylasemia of laparoscopy-assisted surgery for colorectal cancer

Project description:Interventions: Experimental group:none;Control group:none Primary outcome(s): sex;age;body mass index (BMI);concomitant disease;pathological diagnosis;postoperative complications;serum amylase;urine amylase;hemoglobin;white blood cells;lymphocytes;albumin;prothrombin time;the method of operation;the grade of ASA;intraoperative pancreatic operation;the body position of the operation;the method of anesthesia;the pressure of pneumoperitoneum;the duration of pneumoperitoneum;the duration of operation;intraoperative fluid volume;intraoperative urine volume;intraoperative blood loss;intraoperative blood transfusion volume Study Design: Cohort study

| 2676690 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data